Our new Cell Collection Centre, opening in 2025, will be dedicated to providing top-quality apheresis services and ensuring the well-being of our donors. The facility will help lifesaving stem cells quickly reach patients and will also enable donations for cell and gene therapy research.
“The UK healthcare system is working hard to meet this demand and Anthony Nolan is proud to play a role in expanding cell collection capacity. We have nearly one million potential donors on our stem cell register and having our own cell collection centre will ensure they have the best possible experience as well as accelerating patient treatment.
“It also puts Anthony Nolan in the unique position of fully vertically integrating its cell therapy and laboratory services offering, making us the partner of choice for industry looking to bring new cell therapy treatments to patients.”
The centre will be run in partnership with the National Institute for Health and Care Research (NIHR) Nottingham Clinical Research Facility (CRF) at Nottingham University Hospitals NHS Trust.
Nicola Alderson, Chief Operating Officer
Anthony Nolan’s stem cell donors have already helped progress the development of treatments for blood diseases and other conditions. The new centre will complement Anthony Nolan’s existing facilities in Nottingham, including the Cell Therapy Centre at Nottingham Trent University’s Clifton campus, which houses an umbilical cord blood bank as well as our processing and cryopreservation facilities.
We have partnered with Terumo Blood and Cell Technologies, a world-leading manufacturer of specialised medical technologies, who are providing their Spectra Optia™ Apheresis Systems for cell collection at the new centre.
“Patients and donors are at the heart of this growing field of healthcare, and their experience, access and outcomes need to remain the focus.
“Because our Spectra Optia is used in over 67% of white blood cell collections worldwide, we have extensive data and analytics to help inform the standardisation of cell collections, ensuring the best quality cells are collected. We will leverage what we’ve learned through training and technology to help the Anthony Nolan team and its partners optimise each donation.”
Antoinette Gawin, CEO of Terumo Blood and Cell Technologies